Safety and Efficacy of HDP-101 in Relapsed or Refractory Multiple Myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called HDP-101 in patients with multiple myeloma that has come back or stopped responding to previous treatments. The study aims to find the safest and most effective dose and to see if this drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old with a confirmed diagnosis of active multiple myeloma
- You have already had a stem cell transplant OR have been determined to not be eligible for one
- You have received prior treatments including an immunomodulatory drug, proteasome inhibitor, and anti-CD38 treatment (alone or in combination)
- Your cancer is either refractory (not responding) or you are intolerant to standard treatments
- You have adequate organ function (kidneys, liver, heart, etc.) as defined in the study protocol
- You do not have cancer in your brain, plasma cell leukemia, active infections, or hepatitis B or C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment combination for multiple myeloma that has returned or stopped responding to previous therapy and has spread outside the bone marrow. It aims to see if the combination can shrink these tumors and improve outcomes.
This trial tests a new treatment called OL-101 for people whose multiple myeloma has come back or stopped responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. It aims to see if OL-101 can help control the disease.
This trial studies a new treatment called BR101 for people with multiple myeloma that has returned or not responded to previous treatments. The goal is to see if BR101 can help slow down or stop the cancer.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This early-phase trial tests an experimental drug called IMV102 for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The study aims to see if IMV102 is safe and how well it works.
This trial tests a new drug called SG301 added to standard treatments (pomalidomide and dexamethasone) for people with multiple myeloma that came back or got worse after prior therapy. It may help if you have tried lenalidomide and a proteasome inhibitor but your cancer is still active.
Hear when a new Multiple Myeloma and Other Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.